Transplant center directory

The mission of the Cleveland Clinic's Blood and Marrow Transplant Program is to provide high-quality specialized care to patients receiving transplant and cell therapies in a setting of education and research. We embrace the values of initiative, innovation, collaboration, confidentiality, empathy and integrity. The best in high-quality treatment, access to the latest technology and research, and our all-encompassing "Patients First" philosophy make us a leading cancer center. We have expertise in performing autologous and allogeneic transplantation in children and adults with malignant and non-malignant diseases, and offer specialized transplantation procedures such as umbilical cord blood transplant, haploidentical transplant and cellular therapy. We are a certified center for Abecma, Carvykti, Breyanzi, Tecartus, Yescarta and Kymriah Chimeric Antigen Receptor (CAR T-cell) Therapy. Learn more about our Blood and Marrow Transplant Program at clevelandclinic.org/BMT.

This center has been performing allogeneic transplants since 1977 and has been an NMDP/Be The Match transplant center since December 1988.

This center's actual 1-year survival results are below the expected rate for this center.

The survival information we have for this center includes ONLY:

1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2018, 2019, 2020, and
2. Who had their transplant at a U.S. transplant center, and
3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 306 patients.

The actual 1-year survival of these patients is 68.6%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 69.1% and 78.6%.

For help with understanding these statistics, please see Understanding Transplant Outcomes.

For overall survival for all patients transplanted with a specific disease, please see U.S. Patient Survival report at bloodcell.transplant.hrsa.gov.

All diseases

Number of transplants by age reported from January 1, 2020 to December 31st, 2021 (includes marrow, PBSC and cord blood)

Treatments may be similar for diseases within a group. It might be helpful to look at centers that have done transplants for a specific disease and centers that have done transplants for any corresponding broad disease categories.